This article is more than 5 years old. Information may no longer be current.
Top stories in gastroenterology: High-fat diet negatively affects gut microbiota; anti-TNF, Entyvio equally effective for IBD
Among the top stories in gastroenterology last week were study findings that a diet high in fat can lead to unfavorable changes in the gut microbiota and that anti-tumor necrosis factor and Entyvio are similarly safe and effective in older patients with inflammatory bowel disease.
Other popular stories included data that found that early life factors were linked to later IBD development, optimized Remicade monotherapy is effective for IBD induction and elevated fecal calprotectin predicts Crohn’s progression.
High-fat diet linked to unfavorable gut microbiota changes
Eating a diet high in fat and low in carbohydrates can lead to changes in the gut at the microbiome level that could lead to the development of metabolic disorders, according to study results published in Gut. Read more.
Anti-TNF, Entyvio equally effective in older patients with IBD
Anti-TNF alpha antagonists and Entyvio both appeared equally safe and effective among a population of older patients with inflammatory bowel disease, according to study results published in Alimentary Pharmacology & Therapeutics. Read more.
Early life factors linked to later IBD development
Early life events and factors, such as having a mother with inflammatory bowel disease or having an infection within the first year of life, are associated with higher risk for developing inflammatory bowel disease later in life, according to results of a population-based study. Read more.
Optimized Remicade monotherapy effective for IBD induction
Remicade monotherapy with optimized dosing was an effective treatment for patients with inflammatory bowel disease beginning induction therapy, according to data published in Alimentary Pharmacology & Therapeutics. Read more.
Elevated fecal calprotectin predicts Crohn’s progression
Routinely measuring levels of fecal calprotectin can identify patients at risk for Crohn’s disease progression regardless of symptoms, according to study results published in Clinical Gastroenterology and Hepatology. Read more.